SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Celanese Corporation issued a press release on August 4, 2026, reporting second quarter 2026 financial results, including diluted EPS of $1.15, adjusted EPS of $2.45, and net sales of $2.8 billion. The press release is attached as Exhibit 99.1 and incorporated into Item 2.02 disclosure. This is a standard quarterly earnings release with detailed segment performance, cash flow, and forward guidance.
View raw filing on EDGAR →The Item 7.01 disclosure announces that Scott A. Richardson, President and CEO, will present the Company's "financial results for its second quarter 2026" via webcast on August 5, 2026. The filing includes prepared remarks and slide presentations (Exhibits 99.1(a) and 99.1(b)) and a Non-GAAP reconciliation document (Exhibit 99.2) that explicitly references quarterly financial results and performance metrics. This is a classic earnings release disclosure, even though filed under Item 7.01 (Regulation FD) rather than Item 2.02, and is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The Federal Home Loan Bank of Des Moines discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes. Schedule A lists specific debt securities with trade dates in July 2026, settlement dates in August 2026, maturity dates ranging from 2026 to 2046, and principal amounts totaling approximately $1.06 billion. This is a classic debt issuance disclosure under Item 2.03, creating new direct financial obligations for the Bank.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details three specific debt issuances with trade dates in late July 2026, including a $10 million bond at 5.55% coupon, a $20 million bond at 5.18% coupon, and a $500 million variable-rate floater. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations created by the registrant.
View raw filing on EDGAR →ImmunityBio disclosed quarterly and first-half 2026 financial results via press release attached as Exhibit 99.1, including net product revenue of $50.7 million (Q2 2026, up 92% YoY) and $94.8 million (H1 2026, up 121% YoY), along with detailed consolidated statements of operations, balance sheet data, and cash flow summaries. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →The filing discloses the issuance of Consolidated Bonds (debt securities) by the Federal Home Loan Bank of Cincinnati on trade dates of 7/29/2026, with five separate bond issuances totaling $50 billion in principal amount across various maturities (2031–2046) and coupon rates (4.500%–6.000%). This constitutes creation of direct financial obligations under Item 2.03, which is the standard 8-K item for debt issuance. The disclosure includes detailed terms (CUSIP, settlement dates, call provisions, rate types) typical of a debt-issuance filing.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A itemizes multiple debt issuances with trade dates in late July 2026, including fixed-rate bonds (e.g., $5M at 4.625% maturing 6/13/2031) and variable-rate floaters totaling approximately $2.65 billion across multiple maturities. This is a classic debt_issuance event under Item 2.03, and the aggregate principal amount is material to the registrant's financial obligations.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Chicago. Schedule A details multiple debt securities issued on trade dates in late July and early August 2026, with principal amounts totaling approximately $120 million across various maturities and coupon rates. This is a classic debt issuance under Item 2.03, and the Bank explicitly acknowledges that "consolidated obligations issuance is material to the Bank."
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Boston. Schedule A details 11 separate debt issuances with trade dates in late July and early August 2026, totaling approximately $2.77 billion in principal amount. These are new debt obligations created by the Bank, fitting squarely within Item 2.03 and the debt_issuance event type. The materiality is evident from the aggregate principal amounts and the Bank's explicit statement that "certain aggregated issuances of consolidated obligations are material to the Bank."
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Atlanta. Schedule A details eight separate debt issuances with trade dates of 7/29/2026 and 7/31/2026, totaling approximately $4.925 billion in principal amount across variable-rate floater instruments with maturities ranging from November 2026 to March 2027. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations created by the registrant.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a combined par value of $500 million, with settlement dates of 7/30/2026 and 8/4/2026. This represents the creation of new direct financial obligations under Item 2.03, meeting the definition of debt issuance. The materiality is evident from the substantial principal amounts and the explicit disclosure of the bank's primary obligor status on these consolidated obligations.
View raw filing on EDGAR →The filing discloses the creation of a direct financial obligation through the issuance of a consolidated obligation bond by the Federal Home Loan Bank of Dallas. Schedule A reports a $1 billion variable-rate bond (CUSIP 3130BBQS7) with a trade date of 7/29/2026 and maturity of 11/3/2026, representing a new debt obligation. This is a classic debt issuance disclosure under Item 2.03, material to investors assessing the Bank's capital structure and funding activities.
View raw filing on EDGAR →eHealth issued a press release on August 4, 2026 announcing financial results for Q2 and six months ended June 30, 2026, including revenue, net income, adjusted EBITDA, and operating cash flow metrics, along with full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly discloses "Results of Operations and Financial Condition," which is the standard Item for earnings releases.
View raw filing on EDGAR →Equitable Holdings issued a press release on August 4, 2026 announcing Q2 2026 financial results, disclosing a net loss of $453 million ($1.68 per share) and Non-GAAP operating earnings of $488 million ($1.70 per share), along with business segment performance metrics.
View raw filing on EDGAR →This is a press release announcing Ternium's second quarter and first half 2026 financial results, including consolidated net sales of $4.34 billion, adjusted EBITDA of $717 million, and net income of $465 million. The document explicitly states "This report contains Ternium S.A.'s press release announcing second quarter and first half of 2026 results" and presents detailed financial statements, segment performance, and forward guidance—all hallmarks of a quarterly earnings release material to investors.
View raw filing on EDGAR →Primoris Services Corp disclosed Q2 2026 financial results (quarter ended June 30, 2026) showing revenue of $1,688.2 million (down 10.7% year-over-year), net loss of $24.2 million, and Adjusted EBITDA of $11.4 million (down 92.6% year-over-year), with detailed segment results and forward guidance reflecting material challenges in the Energy segment's renewable projects.
View raw filing on EDGAR →On July 31, 2026, the Company's Board of Directors declared a cash dividend of $0.08 per share of common stock, payable on or about October 15, 2026 to stockholders of record as of September 30, 2026.
View raw filing on EDGAR →Allegiant Travel Company disclosed second quarter 2026 financial results, reporting consolidated total operating revenue of $943.5M and adjusted diluted earnings per share of $2.19 (up 78.0% year-over-year), along with full-year 2026 guidance of adjusted EPS greater than $6.00.
View raw filing on EDGAR →Douglas Emmett Inc. disclosed its Q2 2026 financial results on August 4, 2026, by posting its "Second Quarter 2026 Earnings Results and Operating Information package" to its website (Exhibit 99.1). The filing includes consolidated operating results, balance sheets, FFO and AFFO metrics, and updated 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Broadridge disclosed financial results for the fourth quarter and fiscal year ended June 30, 2026, including detailed revenue, operating income, and EPS metrics, along with forward guidance for fiscal 2027.
View raw filing on EDGAR →Broadridge declared a quarterly dividend of $1.09 per share, reflecting a 12% increase in the annual dividend from $3.90 to $4.36 per share (the 20th consecutive annual increase), and authorized a new $1.5 billion share repurchase program.
View raw filing on EDGAR →This is a press release announcing preliminary unaudited financial results for Q2 2026 (ended June 30, 2026), dated August 4, 2026. The document discloses revenue of $7.5 million, net loss of $9.8 million, and diluted loss per ADS of ($0.65), along with detailed financial statements and management commentary. This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →Greenlight Capital Re disclosed financial results for Q2 and six months ended June 30, 2026, including gross premiums written, net premiums earned, underwriting results, investment results, net income/loss per share, and book value per share.
View raw filing on EDGAR →The Company entered into an Ordinary Share Repurchase Agreement with an affiliate of Chairman David Einhorn to repurchase shares equal to 33% of open-market repurchases during a specified period, with the purchase price tied to the weighted average price paid in open-market transactions.
View raw filing on EDGAR →Niagen Bioscience issued a press release announcing Q2 2026 earnings for the quarter ended June 30, 2026, reporting net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights including new product launches and pharmaceutical program developments.
View raw filing on EDGAR →American Well Corporation announced its financial results for the fiscal quarter ended June 30, 2026, on August 4, 2026. The disclosure includes quarterly revenue of $52.0 million, net loss of ($9.6) million, gross margin of 53%, and adjusted EBITDA of ($1.2) million, along with updated full-year 2026 revenue guidance ($200–$205 million) and adjusted EBITDA guidance ($9–$7 million). The earnings report is furnished as Exhibit 99.1 and is typical of Item 2.02 earnings releases. This is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →OPENLANE issued a press release on August 4, 2026 announcing its financial results for the three and six months ended June 30, 2026, including revenue of $555 million (15% YoY growth), net income of $44 million (33% YoY growth), and Adjusted EBITDA of $103 million (19% YoY growth). The company also raised its 2026 consolidated Adjusted EBITDA guidance from $365-$385 million to $385-$400 million. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →The filing discloses the Board of Directors' declaration of regular monthly cash dividends of $0.265 per share for October, November, and December 2026, plus a supplemental cash dividend of $0.30 per share payable in September 2026. This is a straightforward dividend declaration with specific payment dates and amounts, representing total dividends of $1.095 per share and an annualized yield of 7.9%. As a BDC-like investment company with a consistent dividend history since 2007, dividend declarations are material to shareholders.
View raw filing on EDGAR →This is a standard earnings release disclosing Graphic Packaging's second quarter 2026 financial results, including net sales of $2,188 million, net income of $24 million, and adjusted EBITDA of $247 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also includes updated 2026 guidance and discussion of operational performance.
View raw filing on EDGAR →Dr. Molly Carr was appointed as Chief Medical Officer of iBio effective July 31, 2026. The appointment includes compensatory arrangements (base salary of $470,000, 40% target bonus, and a 430,000-share inducement stock option award) and is material to the clinical-stage biotech company as it strengthens clinical leadership during a critical phase of pipeline advancement into the clinic.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 disclosing financial results and operating highlights. The filing explicitly states "On August 4, 2026, Intrepid Potash, Inc. issued a press release announcing its financial results and operating highlights for the second quarter of 2026" with the press release furnished as Exhibit 99.1. The disclosure includes key financial metrics (sales, gross margin, net income, EBITDA), segment performance, production guidance updates, and capital allocation decisions—all hallmarks of an earnings release under Item 2.02.
View raw filing on EDGAR →OrthoPediatrics issued a press release on August 4, 2026, announcing its Q2 2026 financial results, including record revenue of $70.5 million (up 15% YoY), record adjusted EBITDA of $6.8 million, and increased full-year 2026 guidance to $265.0–$269.0 million. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes unaudited condensed consolidated financial statements and detailed segment performance metrics.
View raw filing on EDGAR →Hamilton Lane Incorporated disclosed its financial results for the first fiscal quarter ended June 30, 2026, via press release and detailed presentation furnished as Exhibit 99.1. The filing reports GAAP net income of $124.9 million (up 62% YoY), net income attributable to Hamilton Lane of $80.5 million (up 50% YoY), and diluted EPS of $1.93 (up 51% YoY), along with comprehensive financial statements and business metrics. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →Danka Radosavljevic was appointed Chief Operating Officer on July 31, 2026, a material executive position. While the disclosure also includes compensation details (base salary of $520,800 and 50% bonus target), the principal disclosed action is the appointment to the COO role. The appointment of a C-suite officer is material to investors assessing company leadership and governance.
View raw filing on EDGAR →Superior Group of Companies announced second quarter 2026 financial results, reporting net sales of $147.8 million, net income of $1.2 million, and adjusted EBITDA of $7.7 million, along with full-year 2026 guidance and a quarterly dividend declaration.
View raw filing on EDGAR →CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for dementia with Lewy bodies, providing early and coordinated guidance from the MHRA, NICE, and other HTA bodies designed to accelerate time to market. This is a material regulatory milestone affecting the development pathway and competitive positioning of the company's lead drug candidate.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 financial results for Turning Point Brands, Inc. The Item 2.02 filing announces consolidated net sales of $142.9 million (up 22.6%), net income of $3.6 million (down 75.2%), and includes detailed segment performance, balance sheet, and cash flow statements. The company also raised full-year Modern Oral guidance. The press release is attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release disclosing Chatham Lodging Trust's second quarter 2026 financial results. The press release (Exhibit 99.1) announces key operating metrics including RevPAR growth of 3%, net income of $6.2 million, AFFO per share of $0.48 (up 22%), and updated 2026 guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →The Item 2.02 disclosure announces Lattice Semiconductor's financial results for Q2 2026 (quarter ended July 4, 2026) via a press release furnished as Exhibit 99.1. The press release reports record revenue of $201.1 million (up 62% YOY), GAAP net income of $0.14 per diluted share, and non-GAAP EPS of $0.53 (up more than 120% YOY), along with forward guidance for Q3 2026. This is a standard quarterly earnings release disclosure material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →The disclosure announces a one-for-three reverse split of the Trust's shares, approved by the Sponsor on July 31, 2026, effective October 6, 2026. This is a structural governance action affecting share capitalization and trading mechanics. While reverse splits are routine capital structure events, they are material to shareholders as they affect share count, NAV per share, and trading price, and may have tax consequences. This does not fit a specific named event type but is clearly a governance/capital structure matter.
View raw filing on EDGAR →The filing discloses an amendment to a borrowing base agreement with Citibank that decreased the available borrowing capacity from $115 million to $105 million. While no borrowings are currently outstanding, the reduction in the borrowing base represents a material modification to the Company's credit facility and financial flexibility. This amendment to an existing credit facility falls under debt-related disclosures, though the reduction in available capacity (rather than new debt issuance) creates some ambiguity about the precise event type.
View raw filing on EDGAR →Brenda S. Tudor, a Board member, notified the Company of her resignation from the Board and all committees effective September 8, 2026. The disclosure centers on her departure from the Board due to family health reasons, with no disagreement with the Company. Board departures are material to investors as they affect governance and oversight structure.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly financial results for the period ended June 30, 2026. The filing explicitly states "On July 30, 2026, Horizon Technology Finance Corporation (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2026" and includes detailed operating results, net investment income per share ($0.11), NAV per share ($6.23), portfolio yield (14.9%), and other material financial metrics. The press release is attached as Exhibit 99.1 and constitutes a standard Item 2.02 earnings disclosure.
View raw filing on EDGAR →The filing discloses the Board's declaration of regular monthly distributions totaling $0.18 per share and special distributions totaling $0.09 per share for the fourth quarter of 2026, with specific ex-dividend, record, and payment dates. This is a straightforward dividend declaration by a specialty finance company (BDC), which is material to shareholders as it affects their returns and is a core component of the company's investment thesis.
View raw filing on EDGAR →PAMT CORP disclosed Q2 2026 financial results via press release dated August 4, 2026, reporting total revenues of $164.7 million (up 8.9% YoY), operating loss of $10.4 million, and net loss of $7.4 million ($0.36 diluted loss per share).
View raw filing on EDGAR →Daniel C. Kleine was elected Chief Financial Officer effective July 30, 2026, a material appointment to a named executive officer role with associated compensation arrangements including a salary increase to $300,000 and a 20,000 RSU grant.
View raw filing on EDGAR →The filing discloses both the resignation of CEO Vincent J. Arnone (effective August 10, 2026) and the appointment of Ramesh Nuggihalli as the new Chief Executive Officer and President (effective August 10, 2026). While both events are disclosed, the principal action centers on the appointment of a new CEO following a months-long executive search process. The appointment is material to investors as it represents a significant leadership transition at the company. The compensatory arrangements disclosed in section (e) are ancillary to the appointment itself.
View raw filing on EDGAR →This Item 2.02 disclosure announces Fuel Tech's financial results for the fiscal quarter ended June 30, 2026, with a press release furnished as Exhibit 99.1. The filing reports Q2 2026 revenues of $6.5 million (up 17% YoY), net loss of $(1.2) million, and segment performance details. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial condition and operating performance.
View raw filing on EDGAR →The Company entered into a waiver and release agreement with Aegis Capital Corp. on July 29, 2026, paying $0.7 million immediately and committing to $0.3 million in future payments to waive rights of first refusal and tail fees from prior engagement agreements. This is a material financial obligation and commitment that affects the Company's capital structure and future financing flexibility, but does not fit the specific categories of debt issuance, M&A activity, or other named financial events—it is a settlement or release of prior contractual obligations.
View raw filing on EDGAR →Charlie's Holdings appointed Henry Sicignano III as Chief Executive Officer, effective immediately on August 4, 2026. Sicignano, former CEO of 22nd Century Group, assumes leadership at a critical juncture for the company's regulatory and commercialization initiatives. Ryan Stump transitioned from COO to Board Member and strategic partnerships role.
View raw filing on EDGAR →